Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

New research shows honey fights drug-resistant germs

Herbal ingredients and natural nutrients are often capable of supporting different functions within the body, and current research is showing that a certain kind of honey may be useful in fighting drug-resistant germs.

2 May 2011

Antibiotics may serve as effective treatment for appendicitis than surgery

Antibiotics rather than surgery may be the better treatment for cases of appendicitis in which the appendix hasn't burst, according to a new study.

29 Apr 2011

New innovative pilot project to combat surgical infections

Roughly one out of every 24 patients undergoing surgery acquires a surgical site infection. With 40 million operations performed in the U.S. each year, between 800,000 and 2 million individuals contract these infections annually.

29 Apr 2011

UIC receives federal contract to develop antibiotics against three bacterial infections

Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.

28 Apr 2011

ViroPharma reports net sales of $127 million for first quarter 2011

ViroPharma Incorporated reported today its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

28 Apr 2011

Low-cost colorimetric sensing array identifies bacterial infections

Bacterial infections really stink. And that could be the key to a fast diagnosis.

28 Apr 2011

New angle in cause of tuberculosis discovered - scientists hopeful for new therapy

In a new study published Monday, researchers from the US have isolated the enzyme that allows tuberculosis to destroy lung tissue. This discovery could speed the search for treatments.

26 Apr 2011

Durata attains global rights for dalbavancin to treat abSSSI

Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.

26 Apr 2011

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.

26 Apr 2011

Some bacteria avoid antibiotic treatments by going 'off the grid' like rogue secret agents

Going "off the grid," like rogue secret agents, some bacteria avoid antibiotic treatments by essentially shutting down and hiding until it's safe to come out again, says Thomas Wood, professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University.

26 Apr 2011

Scientists identify key enzyme that destroys lung tissue in TB

Scientists have identified a key enzyme responsible for destroying lung tissue in tuberculosis, they report today in the Journal of Clinical Investigation. Drugs that inhibit this enzyme are already available, meaning that the finding could lead quickly to new treatments.

26 Apr 2011

Group B streptococci continues to increase risk of sepsis in newborns

Bloodstream infections in newborns can lead to serious complications with substantial morbidity and mortality. What's more, the pathogens responsible for neonatal infections have changed over time. In recent years, however, antibiotic prophylaxis given to at-risk mothers has reduced the incidence of early-onset group B streptococcal infections among their babies.

25 Apr 2011

Creative approach can tackle bacterial infections in patients with cystic fibrosis

An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

25 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

USPTO issues patent to Oragenics ProBiora3 for oral care

Florida-based biopharmaceutical company Oragenics, Inc. announced today the issuance of patent number 7931892 from the United States Patent and Trademark office for ProBiora3, a proprietary blend of naturally occurring oral bacteria shown to produce a wide range of oral care benefits.

22 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Immigrant screening fails to detect more than 70% cases of latent tuberculosis infection

Current UK procedures to screen new immigrants for tuberculosis (TB) fail to detect more than 70 per cent of cases of latent infection, according to a new study published in The Lancet Infectious Diseases.

21 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Antibiotic News and Research

Further Reading

New research shows honey fights drug-resistant germs

Antibiotics may serve as effective treatment for appendicitis than surgery

New innovative pilot project to combat surgical infections

UIC receives federal contract to develop antibiotics against three bacterial infections

ViroPharma reports net sales of $127 million for first quarter 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Low-cost colorimetric sensing array identifies bacterial infections

New angle in cause of tuberculosis discovered - scientists hopeful for new therapy

Durata attains global rights for dalbavancin to treat abSSSI

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

Some bacteria avoid antibiotic treatments by going 'off the grid' like rogue secret agents

Scientists identify key enzyme that destroys lung tissue in TB

Group B streptococci continues to increase risk of sepsis in newborns

Creative approach can tackle bacterial infections in patients with cystic fibrosis

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

USPTO issues patent to Oragenics ProBiora3 for oral care

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Immigrant screening fails to detect more than 70% cases of latent tuberculosis infection

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News